Oncotype DX Breast Cancer Test – Personalized Risk Assessment & Treatment Guidance

Description

Oncotype DX Breast Cancer Test

The Oncotype DX Breast Cancer (ML) Test is a groundbreaking genomic test designed to provide personalized insights into the treatment of early-stage, hormone receptor-positive (HR+), HER2-negative breast cancer. By analyzing the activity of 21 key genes within a tumor sample, this test generates a **Recurrence Score® result**, which helps predict the likelihood of cancer recurrence and the potential benefit of chemotherapy.

Key Features & Benefits:

– Personalized Treatment Guidance: The test provides a precise Recurrence Score® (ranging from 0 to 100), helping patients and their doctors make informed decisions about whether chemotherapy is necessary in addition to hormone therapy.
– Clinically Validated: Backed by extensive clinical studies, including the landmark TAILORx and RxPONDER trials, the Oncotype DX test is recognized as a standard of care in breast cancer treatment.
– Minimizes Unnecessary Chemotherapy: By identifying patients who are unlikely to benefit from chemotherapy, the test helps avoid unnecessary side effects, improving quality of life.
– Proven Impact on Outcomes: Studies show that using the Oncotype DX test leads to more precise treatment plans, reducing overtreatment and ensuring that patients receive the most effective therapy for their specific cancer.
– Covered by Insurance: The test is widely covered by Medicare and most private insurance plans, making it accessible to eligible patients.

Why Choose Oncotype DX?

For women diagnosed with early-stage HR+, HER2-negative breast cancer, the Oncotype DX Breast Cancer (ML) Test offers clarity and confidence in treatment decisions. By leveraging advanced molecular diagnostics, it empowers patients and physicians with personalized, evidence-based insights, ensuring that treatment is tailored to the individual’s unique cancer biology.

With the Oncotype DX test, patients can move forward with their treatment plan knowing they are making the best possible decision for their health and future.